June 23, 2025 11:27 AM EDT
R&D

Ex­elix­is' pos­i­tive Phase 3 col­orec­tal can­cer da­ta boost stock

Max Gelman

Senior Editor

Shares $EX­EL of Ex­elix­is jumped af­ter the com­pa­ny re­port­ed pos­i­tive Phase 3 da­ta from one of its can­cer stud­ies.

Ex­elix­is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen plans more grad­ual Mar­i­Tide dos­ing in Phase 3 

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

Lil­ly’s bima­grum­ab boosts weight and fat loss when added to Novo's We­govy

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

The pol­i­tics of vac­ci­na­tion take cen­ter stage as RFK Jr.’s re­built CDC pan­el is set to meet

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times